This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Study of Body-wide Treatments in Atopic Dermatitis Patients

Recruiting
12 years or above
All
Phase N/A
1000 participants needed
6 Locations

Study Overview

The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.

The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Atopic Dermatitis
  • Age: 12 years or above
  • Gender: All

Inclusion Criteria:

  • Patients aged more than or equal to (≥) 12 years at the time of consent.
  • Confirmed diagnosis of AD, of any severity, according to the Investigator's assessment as aligned with International Classification of Diseases 10th revision (ICD-10) code of L20.
  • Prescribed and scheduled to initiate any systemic treatment for AD (including but not limited to biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil)
  • Signed informed consent for registry participation by the patient or parent/legal representative and assent by the patient appropriate to the patient's age, including willingness to participate in long-term follow-up.

Exclusion Criteria:

  • Concurrent participation in an interventional clinical trial that administers an investigational drug that modifies patient care.
  • Insufficient understanding of the study by the patient and/or parent/guardian.

This study investigates the effects and outcomes of systemic treatments in patients with atopic dermatitis (AD). The purpose of this study is to understand the patient journey and assess the safety and clinical outcomes of these treatments in a real-world setting. Atopic dermatitis can vary in severity, and systemic treatments are used for more severe cases to help manage symptoms.

Participants in this study will be observed over time to collect data on their experiences with systemic treatments. The study will evaluate factors such as age, skin color, triggers for AD flare-ups, responses to previous treatments, and any other health conditions participants may have. This information will help researchers understand how these factors impact treatment outcomes across different age groups and geographic regions.

  • Who can participate: Individuals aged 12 years and older with a confirmed diagnosis of atopic dermatitis, who are about to start any systemic treatment, are eligible to participate. Participants must provide informed consent and be willing to engage in long-term follow-up.
  • Study details: Participants will be observed as they receive systemic treatments for atopic dermatitis. This is a non-interventional study, meaning no specific treatment will be assigned, and participants will continue with their usual care.
  • Study timelines: The study will last 5 years.
Updated on 14 Jan 2026. Study ID: NCT07290803

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language